Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2005 | 03-2005 | 12-2004 | 09-2004 | 06-2004 | |
| Assets | |||||
| Current Assets | |||||
| Other current assets | 2,250 | 1,570 | 1,740 | 1,940 | 1,670 |
| TOTAL | $2,250 | $1,570 | $1,740 | $1,940 | $1,670 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 108,970 | 109,520 | 110,080 | 14,010 | 13,980 |
| TOTAL | $108,970 | $109,520 | $110,080 | $14,010 | $13,980 |
| Total Assets | $111,220 | $111,090 | $111,820 | $15,950 | $15,650 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 870 | 900 | 980 | 0 | 0 |
| Accounts payable and accrued liabilities | 7,650 | 6,100 | 9,920 | 1,590 | 1,880 |
| Accrued Expenses | 0 | 0 | 0 | 4,300 | 3,240 |
| Other current liabilities | 710 | 550 | 1,530 | 410 | 400 |
| TOTAL | $9,230 | $7,550 | $12,430 | $6,800 | $6,070 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 5,500 | 5,480 | 5,450 | 5,450 | 5,450 |
| TOTAL | $5,500 | $5,480 | $5,450 | $5,860 | $5,990 |
| Total Liabilities | $14,730 | $13,030 | $17,880 | $12,660 | $12,060 |
| Shareholders' Equity | |||||
| Common Shares | 40 | 40 | 40 | 30 | 30 |
| Other shareholders' equity | -900 | -1,020 | -1,270 | -300 | -310 |
| TOTAL | $373,540 | $373,170 | $372,680 | $270,890 | $270,360 |
| Total Liabilities And Equity | $388,270 | $386,200 | $390,560 | $283,550 | $282,420 |